• The company reported revenues of $9.7M, in-line with Q1 2021’s sales while gross profit improved to $2.1M, up 16% quarter over quarter
• Excellon’s production cost per tonne decreased to $273, down 8% quarter over quarter
• The company also increased its exploration expenditures to $1.8M in Q2 2021, with ongoing mining activity at Mexico’s Platosa mine, as well as in their German and Idaho-based sites

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with precious metal projects in Mexico, Idaho and Germany, has recently published their second quarter results for the 2021 fiscal year. The Company reported Q2 2021 revenues of $9.7 million, up from the $0.7 million registered in Q2 2020, while gross profit improved to $2.1 million, a significant improvement from last year when there was a loss of -$2.6 million. Excellon Resources also reported that the company had cash and marketable securities totalling $7.1 million at hand as of June 30, 2021. Excellon Resources’ strong second quarter results were directly correlated to the robust production numbers generated from the Platosa Mine in Durango, Mexico. Excellon saw silver production of 296,013 ounces, lead production of 1.9 million pounds and zinc production of 2.5 million pounds – in aggregate totalling silver equivalent production of 487,009 ounces. Although comparative results relative to the equivalent period in 2020 were impacted by the suspension of activities in Mexico from April 2, 2020 to June 1, 2020 on account of the COVID-19 outbreak, the second quarter of 2021 marked the fourth consecutive quarter of over 21,000 tonnes mined and milled. “Platosa delivered a fourth consecutive quarter of production at historically high productivity rates,” stated Brendan Cahill, President & CEO of Excellon Resources (https://ibn.fm/eE7Hs). “We continue to see room for improvement, with our ongoing work to improve recoveries at Miguel Auza and, additionally, a sizeable inventory of ore and concentrate at quarter-end due to mill maintenance and weather conditions in late June.” In addition to the high productivity rates witnessed within the company’s operations, Excellon Resources were simultaneously able to reduce their marginal cost of extraction. Production cost per tonne decreased to $273 per tonne, a decline of 8 percent relative to the first quarter of 2021, with the all-in sustaining cost per silver ounce payable decreasing to $26.69 per ounce (https://ibn.fm/KPgIy). Exploration expenditures rose by 597 percent year over year and by 80 percent quarter over quarter to $1.8 million as drilling operations continued to ramp up across various sites. Excellon Resources has recently commenced the process of drilling and adding a second rig at the Silver City site in Germany’s Saxony following the approval of the 2021 drilling operation plan, and it has looked to expand surface and underground drilling operations on multiple targets within the Platosa Mine property. Additionally, the company has commenced drilling at the Oakley Project in conjunction with Centerra Gold Inc. “The operation delivered good improvements in cost-per-tonne and cash costs, while AISC was higher in the quarter due to sustaining capital expenditures, a part of which had been deferred from earlier periods,” stated Cahill. “Most importantly, we continued to ramp-up exploration on our projects, with Platosa ongoing and Silver City and Oakley getting started. We look forward to drilling results from our resource growth and discovery-focused projects through the remainder of the year.” For more information, visit the company’s website at www.ExcellonResources.com. NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

• Canada-based life sciences company Mind Cure Health is pursuing innovative technology and research solutions to improve mental health through technology
• The company is focused on developing digital therapeutics technology and researching psychedelic compounds
• The company’s proprietary software-as-a-service (SaaS) platform iSTRYM is designed to increase transparency and awareness between patients and therapists
• On the research side, Mind Cure Health is also manufacturing synthetic ibogaine and currently determining the commercialization potential of two different pathways for production
• Mind Cure Health recently announced an agreement with experienced clinical psychologist Dr. Ken Weingardt to guide iSTRYM toward near-term commercial deployment

A growing number of researchers in the medical science field are investigating the potential of psychedelic drugs to open a new field of medicinal solutions. Legislators as well as wider segments of society are also beginning to take notice. Canada-based Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) is devoted to building access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. The company has filed a provisional patent application for its pharmaceutical-grade synthetic ibogaine to be used in clinical research and anticipates developing that in conjunction with its software-as-a-service (SaaS) platform iSTRYM, which is designed to help patients and physicians manage psychiatric medications using smart “digital therapeutics” technology. To further the company’s goals, Mind Cure Health announced Aug. 10 an agreement with Dr. Ken Weingardt in which Weingardt will provide consulting services as a senior clinical technology advisor. Weingardt is a clinical psychologist with 20 years of experience working at the intersection of technology and behavioral health, according to the company (https://ibn.fm/bqm92). Weingardt will guide iSTRYM toward near-term commercial deployment, building clinical excellence in both commercial deployment and design. “This company is among the first to develop a digital therapeutic specifically designed to support the process of psychedelic-assisted therapy. I am delighted to advise the team as they leverage innovative technologies to potentially reduce symptoms, improve quality of life, and support transformation and healing,” Weingardt stated in the company’s news release. The company anticipates making iSTRYM available to select clinics during the current Q3 period and launching the software broadly and commercially during the first few months of next year. The product launch will initially be aimed at psychedelic centers but will later expand to integrated clinics, both traditional and psychedelic, and eventually the broader mental health market, according to the company. Mind Cure Health plans to file for FDA approval under the software as a medical device (“SaMD”) pathway, which it expects to speed reimbursement. iSTRYM will be a fee-based service to help clinics ideally create better care and outcomes for their patients. Mind Cure Health’s synthetic ibogaine research aims to develop a potential treatment for traumatic brain injury, neuropathic pain and migraines. The company indicates ibogaine may also help repair and rewire the brain’s neural pathways in treating drug addiction. The company recently announced it had launched the second stage of manufacturing synthetic ibogaine after completing proof-of-concept protocols that tested the chemistry and development route for successfully manufacturing ibogaine. The second stage will focus on the scale-up process by establishing financial models in tandem with assessments of the quality of the synthetic ibogaine to determine the economic viability of commercial scaling (https://ibn.fm/Au7Kn). For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• It has become known that COVID-19 patients can present with neurological symptoms, but new comprehensive cross-country study indicates that it could be more prevalent than previously thought
• This could represent enormous challenge to healthcare as it needs to prepare for immediate and longer-term rehabilitation care of these patients
• Brain Scientific is committed to remaining at forefront of brain diagnostics, potentially offering solution to higher need for neurological care of COVID-19 patients

Brain Scientific (OTCQB: BRSF), a commercial-stage health care company on a mission to modernize brain diagnostics, could be the one offering solution to the rising challenge global healthcare systems face in the post-Covid world. As scientists are starting to collect more and more data, they can decipher both immediate and longer-term consequences of SARS-CoV-2 infection. Research has been mounting demonstrating that some infected patients suffer from neurological symptoms, including memory loss, stroke, and other effects on the brain (https://ibn.fm/CM7uW). However, the new comprehensive cross-country study recently published in the Journal of Neurology, Neurosurgery, and Psychiatry reveals that neurological symptoms may actually be the norm rather than an exception (https://ibn.fm/s3uJw). A new systematic review and meta-analysis conducted by University College London examined 215 COVID-19 studies across 30 different countries involving 105,638 symptomatic COVID-19 patients from January to July 2020. The research team was expecting to find neurologic and psychiatric findings to be more common in severe COVID-19. Instead, they found that some of these symptoms appeared to be more common in mild cases, indicating that COVID-19 affecting the brain could be the norm, rather than the exception as previously thought. The study also demonstrates no clear link of these symptoms to systemic or respiratory symptoms. According to the authors, the most prevalent neurological symptoms actually occurred more frequently in patients with less severe COVID-19. This finding could indicate that neurological symptoms are not necessarily correlated with systemic or respiratory symptoms. As we learn more about COVID-19, it is becoming increasingly clear that neurological care in the post-Covid world will be crucial. In the words of the authors, with millions of people infected globally, even the rarer symptoms could affect considerably more people than in normal times. Due to the sheer scale of the pandemic, this could potentially represent a massive challenge to healthcare systems that need to prepare both for the immediate care of these patients and their longer-term rehabilitation needs. In an environment like this, Brain Scientific’s next-generation technological solutions for the neurology market could become critical as they offer EEG testing to be deployed rapidly and accurately in children and adults alike. The company’s two FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM), allow quick and reliable EEG testing in minutes and by any healthcare worker, not only specialized neurological technicians, bringing brain diagnostics to settings where it was previously impossible or difficult to conduct neurological testing. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Cooperation and partnership discussions: AnPac Bio has reported major corporations in the medical industry include Roche Pharmaceuticals China and Advanced Life Therapeutics Co., Ltd
• AnPac Bio holds 40% minority equity in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devices
• AnPac Bio’s board now includes Mr. Chao Feng who has global fortune 500 Companies’ managerial experience as independent director effective July 19, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), an innovative thought leader and biotechnology company focused on early screening and cancer detection by developing, distributing, and deploying accessible early disease detection devices, announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holding AG, to explore novel healthcare and medical solutions. The collaboration will leverage both parties’ advantages and resources to work on early cancer screening, diagnosis, and treatment (https://ibn.fm/4PpPO). AnPac Bio is an early thought leader and innovator in the field of cancer screening, where it has already made notable contributions including as an early thought leader and technology leader of multi-(pan) cancer screening and multi-level and multi-parameter innovation and screening products. By 2014, AnPac Bio announced that the cancer detection technology it developed was capable of screening 16 types of cancer, and was one of the earliest companies to begin marketing a pan-cancer screening and detection test in 2015, when it began commercial operations. Per the agreement signed by AnPac Bio and Roche, both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (“CDA”) cancer detection technology and Roche’s FoundationOne CDx to create a solution that customers with a high cancer risk level as assessed by CDA and later diagnosed with cancer can receive a personalized CDx precision medical test for therapy selection. The parties aim to help benefit the general population while lowering costs and saving patient lives. Th cancer screening and diagnostic market is expanding, with the number of cancer cases reported worldwide also growing. According to the World Health Organization (“WHO”), there were 135 million cancer patients globally in 2020, with 32 million geographically located in China. The new figures mark a 20 million increase in the number of worldwide cases, 4.7 million of which in China. The cooperation agreement with Roche comes after AnPac Bio’s agreement with Advanced Life Therapeutics Co., Ltd. The company holds minority equity of 40% in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devices (https://ibn.fm/RIHTd). The partnership with Advanced Life Therapeutics is a multi-year contract to design, fabricate, test, and optimize key components of a cancer treatment medical device. AnPac Bio expects to begin generating revenue from this contract R&D project starting Q3 of this year. AnPac Bio is in the later stages of cooperation and partnership discussions with multiple major corporations in the medical industry aimed at increasing commercial CDA-based cancer test revenue and broadening a new product pipeline for itself and its partners. The agreements with Advanced Life Therapeutics and Roche announced recently. Effective July 19, 2021, Mr. Chao Feng was named as her successor to take the role of independent director immediately (https://ibn.fm/IDUPZ), with Ms. Lin Yu resigned as the director of AnPac Bio.  Having previously worked for two global Fortune 500 companies in China, Mr. Chao Feng served as general manager for Shanghai Zhiruihaochen Information Technology Co., Ltd. since 2019. Additionally, he has been the chairman of the strategy committee of Guangzhou Chengding Robots Co., Ltd. since 2016. In his role as the new independent director of AnPac Bio, Mr. Feng said, “AnPac Bio has been recognized in the field of early cancer screening and detection, and I’m excited to be a part of the team. I look forward to contributing to AnPac Bio’s future success as a member of its Board and helping the Company in its further development.” Dr. Chris Yu, CEO and Chairman of the Board for AnPac Bio, welcomed Mr. Feng to the team, praising his experience. “His strong academic background and business management experience, particularly in strategic planning, capital market transactions, and sales, will benefit our Company in our pursuit of long-term growth,” Dr. Yu said. Through its CDA technology, AnPac Bio aims to tackle multiple aspects and challenges of the cancer screening and diagnostics industry. Using the natural biophysical properties of blood and cellular proteins to discover cancerous environments within the body before the tumors form and being powered by a database of over 200,000 samples and cases, CDA has been able to diagnose and identify pre- and early-stage cancers in patients that were previously diagnosed as cancer-free through traditional methods. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

The Q3 Investor Summit is being held on August 17-18, 2021, offering numerous networking for attending companies and investors. The conference will feature 70+ companies and 800 investors, as well as media assets for additional marketing opportunities. The 2-day event will feature small and micro-cap companies attending the conference who can avail its high-quality content offered by distinguished industry speakers. Investors will be attending to learn about the latest investor trends and do business with the presenting companies. The market cap participation includes:

• $100-$300 (22%)
• $300M+ (24%)
• Under $500M (33%)
• $50 – $100M (21%)

The summit’s investors include:

• Family Office (12%)
• HNW (9%)
• Institutional (61%)
• RIAs (18%)

The Q3 Investor Summit has businesses, entrepreneurs and institutions from the healthcare, consumer, financial, technology, cannabis, blockchain and industrial sectors looking for growth, investment and networking opportunities. Startups and emerging growth companies can leverage the investor connections at this forum to expand their business. Investor Summit’s online platform gives new companies and well-established leaders an excellent growth avenue where they can be discovered by the investment community. This exceptional conference is attended by industry stalwarts and has garnered a reputation for introducing new companies to a wide spectrum of the global investment community. The virtual event has a well-lined up presentation schedule. There are 3 topical panels where you can listen in to avail the knowledge and insights imparted by the community influencers. There is also a 30-minute webcast with Q&A, and all the content will be available on the conference website for 90 days. The Q3 Investor Summit’s one-to-one meetings, high-level discussions and engaging keynotes from eminent industry leaders and thinkers should not be missed. For more details, please visit https://investorsummitgroup.com

• Avricore, through its subsidiary HealthTab(TM), will now distribute Abbott’s ID Now(TM) molecular testing device following the first amendment to the supplier distribution agreement between the two companies
• This amendment will allow for an improvement in onsite testing and reporting capabilities for SARS-CoV-2, along with RSV, Influenza A & B and Strep
• Avricore also announced its partnership with Ellerca Health Inc., in a move to utilize Ellerca’s technologies and service while focusing on diabetes screening and management
• Avricore also marked a huge milestone with the HealthTab(TM) system’s deployment in specific Shoppers Drug Mart(R) locations

On July 26, 2021, Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) announced that it had signed its first amendment to its supplier distribution agreement with Abbott. The initial agreement, which was signed on May 31, 2021, was meant to allow HealthTab(TM) Inc., a subsidiary owned by Avricore, to distribute Canada Abbott’s Afinion(TM) 2 plus associated tests for heart disease and diabetes screening in community pharmacies (https://ibn.fm/qUT1L). With the amendment, HealthTab(TM) can now distribute Abbott’s ID Now(TM) molecular testing device. This will further strengthen onsite testing and reporting capabilities for SARS-CoV-2, along with RSV, Influenza A & B and Strep. While announcing the amendment, Hector Bremner, the Chief Executive Officer (“CEO”) of Avricore, noted: “With ID Now(TM) on the HealthTab(TM) network in community pharmacy, patients can know what they have and get focused treatment and prevent spread through better information.” Avricore is a pharmacy service innovator whose focus is on acquiring and developing early-stage technologies that help move pharmacy forward. Through HealthTab(TM), its wholly-owned subsidiary, the enterprise looks to develop actionable health information more accessible to everybody by creating the world’s largest network of rapid testing devices within community pharmacies. In line with this vision to make testing accessible to everyone, the company announced its partnership with Ellerca Health Inc. (https://ibn.fm/nKlGd). This move was intended to utilize Ellerca’s technologies and service, focusing on diabetes screening and management. Ellerca has made a name for itself, given its commitment to improving patient care through innovation and leading technologies. Known for its 360Care(TM) application, the company allows patients to control their treatment, thereby reducing the time of reactionary treatment, along with the costs associated with that. “We’ve already identified several projects where HealthTab(TM) and 360Care(TM) can work together to support patient needs in pharmacy, and we look forward to continuing to work towards collaborating on these efforts,” noted Mr. Bremner. While announcing the collaboration, Daniel Yeboah, the General Manager (“GM”) of Ellerca Health, noted: “Working together with Avricore Health will allow our members to have easy access to A1C testing at local pharmacies and improve the speed of results.” He also added: “By bringing critical health data to a patient’s mobile device quickly and providing the coaching needed to understand the risks, we can continue to move away from just treating disease and support better health outcomes for people living with chronic conditions like diabetes.” To further create the world’s largest network of rapid testing devices within community pharmacies, Avricore, on August 10, 2021, announced that patient testing had begun on the HealthTab(TM) platform within select Shoppers Drug Mart(R) pharmacies (https://ibn.fm/tpewV). These pharmacies will now be offering screening tests to patients with known pre-diabetes conditions and those who have already been diagnosed with diabetes. “We are very excited to pilot Point of Care Testing with HealthTab and the Afinion 2 analyzer at select Shoppers Drug Mart(R) pharmacies,” noted Frank Hack, the Director of Complex Care at Shoppers Drug Mart. “We are committed to improving access to care through our pharmacy network and enabling our pharmacists to drive improved patient outcomes by providing value-added patient care services,” he added. Initially, the program involved 11 locations. However, ever since, the agreement has been updated to 15 different locations. Beta-testing at the first store proved successful, with over 600 results reported and over 90 patients tested. Avricore reckons that this is a huge milestone for the company and an initiative that will continue to advance the company’s mission of making actionable health information more accessible for everybody by creating a network of rapid testing in pharmacy. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Extreme weather events have led to catastrophic conditions across the world, including a 21% YoY increase in US wildfires thus far in 2021
• The situation has led to increased demand for tree, debris clearing services
• Due to extreme heat and ongoing drought, demand for Sustainable Green Team’s end products has seen dramatic increase

In July of 2021, a number of European countries such as Belgium, Germany, Luxembourg and the Netherland were devastated as they were lashed by up to two months’ worth of rain over the course of only two days, on ground which in many cases was “already near saturation” (https://ibn.fm/YjxKG). The floods due to extreme rain events in Western Europe – said to be the worst in a century – have claimed at least 188 lives. Similar extreme climate events have also manifested themselves in North America; California reportedly finds itself in the grips of the worst drought in over 1,200 years while Utah and Nevada have recently witnessed record temperatures. The extreme heat, coupled with a severe and ongoing drought, has led to a 21% year-over-year increase in wildfires—a lamentable situation which in turn has led to record levels of demand for tree and waste disposal services such as those proffered by the Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal. Tree and debris removal has gained increased importance, both to recover sites following catastrophic weather events as well as to prevent future damage. For instance, the City of Malibu’s local government has launched a free, grant-funded fire hazard tree removal and chipper program to help residents prepare for wildfires (https://ibn.fm/c6ArH). “Brush clearance and removing hazard trees are important ways to create defensible space to make your home more fire resistant, help firefighters stay safe while defending your home, and protect the whole community from wildfires,” said Malibu mayor Paul Grisanti. “Here in Malibu, the next big wildfire is just around the corner, not just in peak wildfire season. So it’s up to us all as individuals and as a community to do everything possible to be ready.” SGTM’s subsidiary National Storm Recovery LLC specializes in providing customers with tree services and debris hauling as well as removal and bio-mass recycling, among other services. The company operates a vertically integrated model, which allows it to transform natural waste created by wildfires, hurricanes, ice storms and floods into useful organic products that benefit the environment through tree services. These services include debris hauling, biomass recycling, waste removal, mulch manufacturing, packaging and sales, and the production of playground surface material. The increase in demand for SGTM’s debris clearing services has also coincided with increased demand for the company’s end-products. Sustainable Green Team’s focus on finding environmental solutions for waste products through the manufacture of mulch products has coincided with a greater-than-ever need for such product amidst the record heat wave currently affecting the country. Increasingly, landscape professionals and gardeners are taking advantage of mulch, which helps soil retain moisture and decreases the need for excessive watering (https://ibn.fm/oENLT). “There are a number of advantages to adding mulch in your garden,” states a recent “Better Homes and Garden” article. “In the summer, mulch helps the soil hold moisture so you don’t have to water as often. In the hot sun, soil also tends to dry out faster and harden. Mulch will help protect the soil from baking in direct sunlight and keep your plants happy” (https://ibn.fm/NLREO). To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/LsNF9. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Company reported various lithium oxide volumes at LC21-22 and LC21-003 drill holes
• The drilling showed irregular values of rare metals, including niobium, rubidium, tantalum, beryllium, cesium, and iron
• Analysis of the samples is done through a process called Code Ultratrace 7 using Peroxide Fusion, ICP, and ICP/MS
• First Energy Metals granted incentive stock options to certain directors, officers, and consultants to purchase up to 900,000 common shares under the Stock Options Plan, exercisable for five years at a price of $0.25 per share
• Global Li-ion Battery Market to Reach $80.5 Billion by 2024

First Energy Metals (CSE: FE) (OTCQB: FEMFF), a publicly-traded Canadian mineral exploration company with a primary focus on developing a multi-commodity mineral property portfolio by identifying, acquiring, and exploring the North American mineral prospects, has announced the results of drill hole LC21-22 at the Augustus Lithium Property in Quebec. The drill hole intersected a 10.5-meter-wide zone with 1.22% lithium oxide at 69 meters drilled depth (https://ibn.fm/qSsQl). There were irregular values of other rare metals found, including average values of niobium, rubidium, tantalum, beryllium, cesium, and iron. The samples collected were bagged, tagged, and delivered to Activation Laboratories in Ancaster, Ontario, for sample preparation and analysis. Activation Laboratories is an independent commercial, accredited ISO-Certified laboratory. Earlier in July, First Energy Metals announced the results from another drill hole at the Augustus Lithium Property. Drill hole LC21-003 intersected a six-meter-wide zone with 0.62% lithium oxide at 45 meters drilled depth, including a two-meter intersection with 1.35% lithium oxide at 48 meters depth. A second two-meter intersection at 73 meters depth assayed 0.63% lithium oxide (https://ibn.fm/BbLHL). Samples from both Augustus Lithium Property drill holes were analyzed using Code Ultratrace 7 – Peroxide Fusion – ICP and ICP/MS. Code Ultratrace 7 fuses the samples with sodium peroxide in a Zirconium crucible. The fused sample is acidified with concentrated nitric and hydrochloric acids. The solution is then diluted and measured by ICP-OES and ICP-MS. The Augustus Lithium Property and the surrounding areas total 14,367.71 hectares and are equipped with excellent infrastructure support, including a road network, railway, water, electricity, and trained manpower available locally. Highlights of the property also include:

• A geographically similar structure to Sayona Mining’s Authier Lithium project and Mine Quebec Lithium Project, which is located approximately 6 to 12 km away
• Documented historical drilling in over 62 drill holes that amount to $2 million in present-day exploration expenditures
• Two prominent lithium and one silver prospect located on the property
• A potential high-grade lithium resource target of 4 million tonnes at 1% lithium oxide
• Potential for large volume low-grade bulk tonnage near the surface
• A two-phase exploration work program

First Energy Metals also has other mining properties located in Quebec. In addition to Augustus Lithium Property, the Company has the Titan Gold, located in the Detour-Fenlon Greenstone Belt in east-central Quebec. Additionally, the company granted incentive stock options to certain directors, officers, and consultants to purchase up to an aggregate of 900,000 common shares under its Stock Option Plan. These will be exercisable for a period of five years at a price of $0.25 per share. The option is subject to a four-month hold period and subject to Canadian Securities Exchange approval. First Energy Metals is well positioned to leverage growing opportunities on the global lithium-ion battery market. Lithium-ion batteries (Li-ion batteries or LiB) are increasingly becoming the rage due to its potential for use in a wide range of products and applications ranging from smartphones and smartwatches to electric vehicles (“EVs”) and energy storage systems. Since being launched commercially in 1991, Li-ion batteries have witnessed significant improvements in performance and capabilities, thus making them indispensable for a range of products. Amid the COVID-19 crisis, the global market for Li-ion Battery is projected to reach US$80.5 Billion by 2024, registering a compounded annual growth rate (“CAGR”) of 15.2% over the analysis period. Europe represents the largest regional market for Li-ion Battery, accounting for an estimated 32.4% share of the global total. The market is projected to reach US$32.8 Billion by the close of the analysis period. Europe is forecast to emerge as the fastest growing regional market with a CAGR of 17.0% over the analysis period (https://ibn.fm/t08YI). For more information, visit the company’s website at www.FirstEnergyMetals.com. NOTE TO INVESTORS: The latest news and updates relating to FEMFF are available in the company’s newsroom at https://ibn.fm/FEMFF

• FuelPositive Corporation is at the forefront of endorsing clean energy and putting systems in place to achieve that goal
• With its technology, the company is helping to reduce carbon dioxide emissions associated with the production of ammonia
• FuelPositive is also positioning itself to capitalize on the growth of the global green ammonia market, set to grow by a CAGR of 54% between 2020 and 2025
• It is also pushing for green ammonia as a replacement for fossil fuels in transportation, enabling a hydrogen economy and offering a new clean option for grid storage

On Monday, August 9, 2021, the United Nations (“UN”) climate panel released the Climate Change 2021 report. The science-backed study warned that the world is already bound to face further climate disruptions, with some of the changes already playing out, including warming oceans, extreme weather conditions, and rising sea levels (https://ibn.fm/O7QoT). António Guterres, the UN Secretary-General, termed the findings as a “code red for humanity.” He further added that the “alarm bells are deafening, and the evidence is irrefutable (https://ibn.fm/Gu9G5).” Of note, from the report is the human influence on climate change, which remains undisputed. Decades of harmful human activity have brought the world to where it is today. In 2021 alone, heatwaves have killed hundreds of people and animals in the Pacific Northwest. Additionally, there are wildfires in the west of the United States and the Siberian forests, all of which are driving people away from their homes (https://ibn.fm/ncYkL). The need and the push for clean energy are needed now more than ever, and companies such as FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) are at the forefront of not only endorsing that but also putting systems in place to achieve that specific goal. FuelPositive Corp. is a growth-stage enterprise whose focus is on partnership, licensing, and acquisition opportunities, building on various technological achievements. Its paramount commitment is to offer commercially viable and sustainable clean energy solutions including, but not limited to, carbon-free ammonia (“NH3”) that can then be used in a range of applications and is used primarily in agriculture. FuelPositive Corp. is at the forefront of pushing for green ammonia, not just in agriculture, but also in other sectors such as energy production and transportation. The economic viability is present, particularly given that the global green ammonia market is set to grow by a compounded annual growth rate (“CAGR”) of 54% between 2020 and 2025 (https://ibn.fm/pAo5x). In addition to pushing for green ammonia, FuelPositive is also driving the narrative associated with green ammonia adoption. Most notably, the company is encouraging the adoption of carbon-free NH3 in transportation, thereby doing away with fossil fuels. As a replacement, ammonia’s only emissions will be water vapor instead of fossil fuel’s carbon dioxide (https://ibn.fm/iHHhq). This will contribute significantly to a greener planet. As for any Nitrous Oxides generated during internal combustion in vehicles, they would be eliminated through catalytic converters. In agriculture, they will be addressed by injecting the liquid fertilizer deep into the ground, which is already standard in farming today. FuelPositive also notes that with its carbon-free NH3, it will be easier to make electricity more accessible to remote communities. Additionally, it will offer long-term storage of excess electricity for energy grids. This will reduce the current overreliance on fossil fuels for energy generation while eliminating the wastage of excess electricity due to improper, unreliable, and unsustainable long-term storage options. Green ammonia involves the production of ammonia through a process that is carbon-free and 100% sustainable. Typically, ammonia is commonly made from water, air, and methane through a method referred to as steam methane reforming (“SMR”) for hydrogen production and the Haber process. About 90% of the carbon dioxide produced comes from the SMR process, cumulatively contributing 1.8% of the global carbon dioxide emissions. The entire process is also known to consume a lot of energy. With FuelPositive’s green ammonia, hydrogen is sourced from water electrolysis, while nitrogen is separated from the air. These are then fed into the company’s in-house core technology, which results in ammonia production. The technology is currently patent pending. With the world growing more conscious about global warming and its effects globally, society is realizing that something needs to be done sooner rather than later. FuelPositive is at the forefront, providing clean energy solutions and addressing a sector whose role in global warming is significant. FuelPositive’s unique technology fits perfectly in a world and an industry that is committed to going carbon-free. With so much ammonia being used in agriculture, the company’s technology can significantly reduce fertilizer-related carbon emissions in this sector. The company is positioning itself to capitalize on the global green ammonia market set for growth in the coming years. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Kasa, Flora’s food and beverage division, announced that it had completed its first purchase order valued at approximately US$1.1m
• This fulfillment is in line with the sales agreement with Tropi, the largest distributor in Colombia, that dates back to July 2021 and is set to last for a year
• This initial sale demonstrated the company’s ability to follow through with its commitments
• Flora is also set to hold its earnings call for the first half of the 2021 fiscal year
• The virtual event is scheduled for Thursday, August 19, 2021, at 4:30 p.m. E.T.

Back in July 2021, Flora Growth (NASDAQ: FLGC), through its food and beverage division, Kasa Wholefoods Company S.A.S. (“Kasa”), inked a sales agreement with Importaciones y Asesorias Tropi S.A.S. (“Tropi”), the largest food and beverage distributor in Colombia. The agreement was intended to last up to one year, with Flora projecting revenue generation of up to US$10 million over that period (https://ibn.fm/pbAdx). In August 2021, Kasa announced that it had completed the first purchase order in line with the agreement. The purchase order, valued at approximately US$1.1 million, marked a key milestone for Flora and also demonstrated the company’s ability to follow through with its commitments (https://ibn.fm/r2rj6). While making the announcement, Jason Warnock, the Chief Revenue Officer (“C.R.O.”) of Flora, noted: “We believe this initial sale demonstrates Flora’s ability to rapidly follow through on its commitments and marks a major turning point for our Kasa Wholefoods division.” He further added, “We expect this relationship with Tropi to generate significant revenue potential in both the short and long term as we build upon a relationship with the leading food and beverage distributor in Colombia.” Flora is an internationally focused cannabis brand builder. It is known for leveraging natural, cost-effective cultivation practices to supply cannabis derivatives to its different product divisions, including pharmaceuticals, natural wellness, hemp textiles, cosmetics, food and beverage. The company also currently operates one of the largest outdoor cultivation facilities in the world. Its fundamental goal /is to market a higher-quality premium product at competitive market prices. Tropi, on the other hand, is an enterprise committed to developing commercial and logistical strategies that allow for the positioning of consumer packaged goods (“C.P.G.”) across different categories through various distribution models, with a focus on the Colombian market. Since it was founded back in 1996, it has made a name for itself by offering healthy and quality products, excellent customer service, and commitment to meeting customers’ needs. With this initial sale, Flora hopes to increase its monthly sales to US$2 million as it further ventures into the newly permitted product category of cannabis-containing ingestible products. This milestone is a move towards the company maximizing the value of the relationship with Tropi, allowing for its growth and expanding its product line. Flora is also set to hold its earnings call for the first half of the 2021 fiscal year. The call, which will be held via webcast, is scheduled for Thursday, August 19, 2021, at 4:30 p.m. Eastern Daylight Time, right after market close (https://ibn.fm/FtBcT). The webcast will have Flora’s management deliver financial results, offer operational updates and even comment on recent growth as well as mergers and acquisition (“M&A”) initiatives announced since the company got listed on NASDAQ back on May 11, 2021. The event will also have a question-and-answer session where investors, the media, and analysts can seek clarification or ask specific questions that they might have. If you wish to participate in the webcast, you can register via this link: https://ibn.fm/IhJgn If any member of the investment community needs access to a phone dial-in, please email flora@cmwmedia.com and one will be provided promptly. For those who would simply like to listen to the replay of the call, here are the available options: Canada/USA: 1-844-512-2921 International Toll: 1-412-317-6671 Replay Access Code: 13722364 The replay dial-in service will be available after 7:30 p.m. Eastern Daylight Time until September 3, 2021 The live webcast will also be accessible online via the link shared above. It will then be archived and available on Flora’s website within approximately 24 hours. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC